

New Variations in the Promoter Regions of Human *DOCK4* and *RAP1A* Genes, and Coding Regions of *RAP1A* in Sporadic Breast Tumors

Akram Jalali¹, Hassan Ebrahimi¹, Mina Ohadi¹, Masood Karimloo², Atena Irani Shemirani³, Behrokh Mohajer³, and Hamid Reza Khorram Khorshid^{1,3*}

1- Genetic Research Centre, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran

2- Epidemiology and Biostatistics Department, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran

3- Reproductive Biotechnology Research Centre, Avicenna Research Institute, ACECR, Tehran, Iran

Abstract

Breast cancer is the most common cancer among women in developed countries. The prevalence of the disease is increasing in the world. Its annual incidence among Iranian women is about 7000 cases. *RAP1A*, a tumor suppressor gene, is located at 1p13.3 and plays an important role in the cellular adhesion pathway and is involved in the pathogenesis of breast cancer. The *DOCK4* gene, which is located at 7q31.1, specifically activates *RAP1A* gene. In the present study, DNA samples from 64 cases of sporadic breast tumors (referred to Mehrad Hospital in Tehran) were screened using PCR-SSCP method and the number of observed variations compared with the control group (100 normal women). Mutation detection for coding exons of *RAP1A* gene and the 500 bp upstream of transcription initiation site as promoters of both *DOCK4* and *RAP1A* were carried out and compared with the control group. The promoter region of *DOCK4* showed a heterozygous mutation with G>A transition at nucleotide -303 in a fibroadenoma case. With regard to *RAP1A* we found a heterozygous mutation, G>A transition in an adenoid cystic carcinoma case, and another heterozygous mutation, G>T transversion in an intraductal papilloma case both at nucleotide +45. A homozygous variation, T>A transversion was also found at nucleotide +29 of a fibroadenoma case. The differences in the frequency of variations mentioned above were not statistically significant. However Fisher's exact showed significant difference for T>A transversion. Although, the higher frequency of these mutations and variations may be related to the disease, a larger sample size is needed for the confirmation of our findings.

Avicenna J Med Biotech 2009; 1(2): 117-123

* Corresponding Author:

Hamid Reza Khorram Khorshid, M.D., Ph.D., Genetic Research Centre, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran

Tel: +98 21 22180084-92

E-mail:

hrkk1@uswr.ac.ir

Received: 5 Feb 2009

Accepted: 25 Apr 2009

Keywords: *DOCK4*, Loss of heterozygosity (LOH), PCR-SSCP, *RAP1A*, Sporadic breast tumor

Introduction

Breast cancer is the most prevalent cancer among women and is the second cause of cancer death in developed countries. In North America and Europe 25% of total cancers in women belong to breast cancer (approximately 20% of women deaths). The prevalence of this disease is increasing to the extent that 1/8 women are possibly affected⁽¹⁾. Among Iranian women, breast cancer incidence rate is about 1/10-1/12 and is the first leading cause

of cancer death. Different studies in Iran indicate that the incidence of breast cancer in women is 22 per 100,000. The prevalence in the same population was 120 per 100,000⁽²⁾. Breast cancer is classified into two types in terms of original cause of the disease; hereditary and sporadic. Five to ten percent of total breast cancers are hereditary (familial) and the rest are sporadic.

Mutations in *BRCA1* and *BRCA2* account

for about 80% of the hereditary type. Furthermore, *P53* gene mutations which occur in 50% of human cancers are known to be one of the main causes of breast cancer⁽³⁾. Tumor Suppressor Genes (TSG) play important roles in different stages of cell cycle and in inhibition of uncontrolled cell proliferation. It has been known that alteration of these genes contribute to sporadic breast cancers.

When both alleles of these genes are inactivated, the cells become cancerous. Loss of heterozygosity (LOH) is one of the phenomena that inactivates the alleles of these genes⁽⁴⁾.

DOCK4 and *RAP1A* genes are located at chromosomal loci in which high frequency LOH is observed. The protein expressed by *RAP1* gene is a small GTPases which belongs to the RAS super-family and shows 50% amino acid sequence homology with RAS⁽⁵⁾.

In addition to the main functions of *RAS* and *RAP1* in cell proliferation and differentiation, *RAP1* also plays some important roles in the regulation of cell adhesion in epithelial tissue⁽⁶⁾.

Cytogenetic abnormalities on the short arm of chromosome 1, *i.e.* 1p13, are the most prevalent chromosomal aberrations in breast cancer. LOH studies show frequent deletions in 1p22, 1p13, 1p31-32.2 loci in relation to breast cancer. Structural changes in chromosome 1 especially disarrangements in band 1p13 are the common cause of cytogenetic abnormalities in breast cancers. Mitchel et al showed that 20% of 113 breast tumors contain LOH in 1p13 locus⁽⁵⁾. In this context, Bieche et al demonstrated the involvement of two regions in chromosome 1p deletion in breast tumors. One of these deletions harbor *Dock4* gene. In his study, using DIS457 and DIS453 markers, the frequency of LOH occurrence was estimated at 34.3% and 21.8%, respectively. Considering the fact that the aforementioned markers are located at 1p13 locus, these findings most probably indicate that one or two suppressor genes reside at 1p32 band

where LOH has been frequently observed in human breast cancer^(7,8).

The *DOCK4* gene, a member of the CDM gene family, is located at chromosomal locus 7q31 and is involved in activation and regulation of small GTPase protein family including *RAP1*. Therefore, *DOCK4* is a tumor suppressor gene and encodes a protein which regulates and affects intercellular junctions through activation of *RAP1* and is disrupted during tumorigenesis⁽⁹⁾.

Marker D7S523 on chromosome 7q31 is frequently deleted due to LOH, in human prostate, ovarian and breast cancers⁽¹⁰⁾. This marker is located at the first intron of *DOCK4*⁽¹¹⁾. Schmutzler et al and Sztanm et al showed that a high frequency of allelic loss (LOH) at D7S523 marker in human breast cancer indicates the presence of a tumor suppressor gene at this region^(12,13). In another study by Balkhi et al, it was revealed that *DOCK4* gene was not expressed in 53% of patients with breast cancer. The difference between patient and control groups was significant⁽¹⁴⁾. This result indicated that *DOCK4* gene expression is disrupted in breast cancer patients. The promoters are involved in gene expression regulation, warranting mutation analysis on the *DOCK4* promoter.

Materials and Methods

This research is a series of case studies. The groups studied (64 cases) were randomly selected from women having breast tumors who were admitted in Mehrdad hospital from October 2004 to December 2005. The criterion for inclusion was the pathological confirmation of breast cancer diagnosis (sporadic invasive ductal breast cancer) or the presence of benign breast tumor. The criterion for exclusion consisted of the existence of breast cancer in the family. For all patients a questionnaire regarding their clinical and pathological history was completed. The results in case group were compared with 100 normal and healthy women (control group).

Consent forms were signed by all patients. All samples were analyzed while they were unknown to the examiner. All related information about *DOCK4* gene such as complete gene sequence, presence of SNPs in exons, mRNA and protein sequences were collected from Ensembl and NCBI related data bases (15, 16).

Around 500 bp upstream of transcription initiating site was considered as promoter region and analyzed for the presence of promoter-specific sequences using McPromoter promoter prediction program (17). Multiple alignment of human and mouse (*Mus musculus*) *Dock4* genes were carried out using DiAlign multiple alignment program (18). Transcription factors binding sites in both mouse and human promoter regions were analyzed and compared by ConSite program (19). Tandem repeats were analyzed using Tandem Repeats Finder Program (20). Using Primer3 program, 3 sets of overlapping primers were designed for 500 bp upstream of transcription start site as promoter region of *DOCK4* and *RAP1A* gene (21).

For each coding exon of *RAP1A* gene a pair of primers extending from the flanking introns was designed as well. DNA was extracted from tumoral tissues by both standard method (phenol/chloroform) and DNA extraction kit (DNPTM, Cina Gene) according to manufacturer's instructions. DNA from blood was extracted using salting out method. Primer sequences are shown in tables 1 and 2.

PCR reaction was performed in a total volume of 25 µl in 0.2 ml Eppendorf tube using Eppendorf thermal cycler. The reaction mixture consisted of 30 ng DNA template, 10 pmol of each primer set (constructed by TAG Copenhagen), 0.3 U of Taq polymerase

Table 1. Primer sequences for the amplification of *DOCK4* promoter region

Primers 5' → 3'	PCR product size (bp)
DOCK4 pro1F: AAATATGACAGAGGGTTCACG	251
DOCK4 pro1R: TGTGAGGAGGTTGTTTATAAGG	
DOCK4 pro2F: GTCCTTAAAGGAGCTCTCAGG	245
DOCK4 pro2R: TTACATGTTATTGACTAGGAAAAATG	
DOCK4 pro3F: GGTAAGCAAATGGATGCAG	284
DOCK4 pro3R: TACACAATATATCAATGCTATCACTC	

Table 2. Primer sequences used for the amplification of promoter and exon-coding regions of *RAP1A* gene

Primers 5' → 3'	PCR product size
RAP1pro1F: TTCATTCCATAAGCATTTCCTTC	249
RAP1pro1R: TCAATATGTGCCGCCAGTG	
RAP1pro2F: CAAGAACTGCGAGTGAATGC	227
RAP1pro2R: TGCACCACCCTGAGTTAAGC	
RAP1pro3F: AAGTGCAGGAGGCTAAAGC	228
RAP1pro3R: GGCAGTGGATCTTTTGTTC	
RAP1Ex3F: TTTTGTGTTTTCAGATCGTC	174
RAP1Ex3R: AGTCTGAAAGCAAGGAAATGTC	
RAP1Ex4F: AAGTAACATTCAAAGGAGTTTCC	161
RAP1Ex4R: TAAGCATGTGTACAAGTTTCAC	
RAP1Ex5F: GGTGGGAAGAAAACAGAATGAG	184
RAP1Ex5R: CAGATGACAAAACCTGCTCAC	
RAP1Ex6F: ATGCTGTTTTAAATTGTTGCAG	252
RAP1Ex6R: GATGGCATAACATCTTACAGAGAG	
RAP1Ex7F: AATGAGTATGTTATTGTTTACG	266
RAP1Ex7R: AAGGCACTTGTGTTGTGCTG	
RAP1Ex8F: AAAGTCTCAAAAACCTGGTGGAG	207
RAP1Ex8R: GAGCATGAGAAAGGCACTTG	

(Supper Taq), 1.5 Mm MgCl₂ and 0.2 Mm dNTPs (Merck). The denaturing, annealing and the extension-time length as well as the temperature for each set of primers were optimized and are shown in table 3. Initial denaturation and final extension time and temperature were (3', 94 °C) and (7', 72 °C), respectively.

First, PCR products were run on 8% acrylamide gel to observe the desired band at the right size. To perform SSCP analysis, PCR product obtained from *DOCK4* -Pro1& 2 and also *RAP1*-Ex 3& 4 were run on 10.5% acrylamide gel and other PCR products were run on 9.5%. Once acrylamide gel was made, it was kept in the fridge for 1 hr to reach 4 °C temperature. Then, gel was put on SSCP tank. PCR products were mixed with an equal volume of loading buffer (PCR gel electrophoresis loading buffer and 90% formamide). Tubes were immediately put on mixture of crushed ice and water for 5 min and afterwards the prepared samples were run on SSCP gel. Marker with the quantity of 150 ng was loaded along side the gel. Table 4 shows the running condition of SSCP gel.

To determine any nucleotide change, the shifted samples on SSCP gel along with normal sample from the same PCR product were sequenced using Chain Termination Method (Microgene Co).

Table 3. The amplification condition

Name of fragment	Denaturing time	Annealing time	Extension time	Number of cycles
<i>DOCK4</i> Pro1	94°, 30"	62°, 25"	72°, 45"	35
<i>DOCK4</i> Pro2	94°, 30"	60°, 15"	72°, 45"	29
<i>DOCK4</i> Pro3	94°, 30"	60°, 25"	72°, 45"	35
<i>Rap1</i> Pro1	94°, 30"	60°, 20"	72°, 45"	25
<i>Rap1</i> Pro2	94°, 30"	59°, 20"	72°, 45"	30
<i>Rap1</i> Pro3	94°, 30"	58°, 20"	72°, 45"	30
<i>Rap1</i> Ex3	94°, 30"	62°, 25"	72°, 45"	35
<i>Rap1</i> Ex4	94°, 30"	62°, 25"	72°, 45"	35
<i>Rap1</i> Ex5	94°, 30"	62°, 15"	72°, 45"	30
<i>Rap1</i> Ex6	94°, 30"	58°, 15"	72°, 45"	30
<i>Rap1</i> Ex7	94°, 30"	61°, 9"	72°, 45"	30
<i>Rap1</i> Ex8	94°, 30"	60°, 15"	72°, 45"	0

Results

Bioinformatical analysis of the *DOCK4* gene

DOCK4 contains 53 exons and encodes a protein consisting of 1954 amino acids. *DOCK4* has 5 domains and is an intramembrane protein. The *Dock4* protein is a member of Dock protein family (*DOCK1* to *DOCK11*) which all contain dedicator of cytokinesis motif. This motif consists of 200 amino acids and has guanyl-nucleotid exchange factor activity. Frequent splicing results in 6 mRNAs coding for 6 protein isoforms^(15, 16). This gene contains 9 SNPs in exons 5, 9, 17, 24, 44 and 52 which results in amino acid changes in constructed proteins⁽¹⁵⁾. No promoter-specific sequence was recognized in 500 bp upstream of the transcription initiation site using McPromoter promoter prediction program⁽¹⁷⁾. Mouse and human sequences alignment of this region using DiAlign program showed 88% homology⁽¹⁹⁾. No homo-

Table 4. Voltage and time of electrophoresis on SSCP gel for each PCR product

Name of fragment	Voltage	Running time (hrs)
<i>DOCK4</i> Pro1	380	6
<i>DOCK4</i> Pro2	320	7
<i>DOCK4</i> Pro3	150	15.5
<i>Rap1</i> Pro1	180	16
<i>Rap1</i> Pro2	180	16
<i>Rap1</i> Pro3	180	16
<i>Rap1</i> Ex3	305	7
<i>Rap1</i> Ex4	305	6
<i>Rap1</i> Ex5	140	15.5
<i>Rap1</i> Ex6	180	18
<i>Rap1</i> Ex7	180	18
<i>Rap1</i> Ex8	180	16

logy was observed between transcription factors binding sites in mouse and human *Dock4* gene using Consite program⁽¹⁹⁾. Also, Tandem repeats finder program could not find any tandem repeat at either promoter or at 5' upstream or 3' downstream regions of the gene⁽²⁰⁾.

Mutation analysis of the genes

PCR products were run on %8 acrylamide gel and were observed after silver nitrate staining (Figure 1).




Figure 1. PCR amplified products of *DOCK4* and *RAP1A* genes, M: 100 bp DNA ladder; *PRO1*, *PRO2* and *PRO3*: Different regions of *DOCK4* gene promoter; *EX3*, *EX4* and *EX5*: PCR amplified fragments (exons 1, 2 and 3) of *RAP1*

SSCP analysis of the samples

There was no band shift in sequences obtained from primer sets *DOCK4*, *PRO2* and *PRO1*. However, one band shift in *DOCK4*, *PRO3* sequence was found. The sample was from a patient who had fibroadenoma breast mass. Sequencing analysis showed a C>G heterozygote variation. This variation is located at position -303 (303 nucleotide upstream of the transcription start site) and +224 of the PCR product sequence (Figure 2). No shift was observed in control group samples.

No band shift was observed in PCR




Figure 2. *DOCK4* and *PRO3* PCR products of patient's samples, M: 100 bp DNA Ladder; S1-S7: samples; The PCR product size is 284 bp and single strand is separated in 500 bp and 560 bp. In sample 5, an obvious band shift is observed

products obtained from *RAP1A* exon (3, 4 and 6) and promoter regions. Three shifts were observed in *RAP1* exon3 sequence which all belonged to introns. Sequencing analysis of PCR product from sample 4 (obtained from a patient with cystic adenoid carcinoma) showed a heterozygote mutation with G>A transition. This variation was located at position +45 from the intron starting point and +146 from 5' site of the PCR product. Sequence analysis of sample 8 that belonged to a patient with breast tumor (intraductal papilloma) showed a heterozygote mutation (G>T transversion) at the same site as it was observed in sample 4. T>A transversion was detected from sample 6 obtained from a patient with fibroadenoma. This variation is located at position +29 from the starting site of the intron and +130 from the 5' region of the PCR product (Figure 3). SSCP analysis of the control samples however did not reveal any band shifts.




Figure 3. *RAP1A*. EX3 PCR products from patient's samples, M: 100 bp DNA Ladder marker; S1-S11: *RAP1*.EX3 PCR products from different samples; the size of PCR products are 174 bp. Two band shifts in single-strand sequences are observed at positions around 290 and 340 bp. There are 2 faint bands of single-strand sequences at positions around 265 bp and 315 bp which are not found in S4 and S8. All bands are more intense in S6

Statistical analysis

Fisher's exact test showed that C>G variation in *DOCK4* gene is independent from the type of the disease ($p=0.13$). Proportion of C>G mutation was higher in patients with breast tumor than the normal group. However this difference was not statistically significant ($RR= 14.22$, 95% CI = 0.7-842).

Fisher's exact test showed that occurrences of *RAP1A* gene with G>T and T>A variations ($p= 0.13$) as well as G>A mutation ($p=0.329$)

are independent from the type of the disease. Although the proportion of patients carrying G>A mutation was also higher in cases with breast tumor compared with the normal group, the increase was not statistically significant ($RR=4.17$, 95% CI = 0.21-247).

Furthermore, we found one case of homozygote variation (two allelic variations, T>A) among 15 cases of benign breast tumor. This is equivalent to two variations among 30 alleles. On the other hand no variation of this type was found among 100 normal subjects in the study which is equivalent to 200 alleles. When we compared the two groups using the Fisher exact test, the observed difference was statistically significant ($p=0.017$).

Discussion

In addition to important roles of RAS and *RAP1* in cell proliferation and differentiation, *RAP1* regulates cell adhesion in epithelial tissues⁽⁶⁾. LOH studies on chromosome 1 in different malignancies exhibit frequent deletions in 1p22, 1p13 and 1p31-32.2 loci. Structural chromosome 1 changes, specifically disarrangements in band 1p13 are the common cause of cytogenetic abnormalities in breast cancers⁽⁵⁾.

DOCK4 gene, a member of CDM gene family, resides at long arm of chromosome 7 (7q31) and is known to be a tumor suppressor gene. *DOCK4* is involved in activation and regulation of small GTPase protein family specifically *RAP1*, and hence stimulates the formation of intercellular junctions. *DOCK4* mutations found in prostate and ovarian cancers prevent *RAP1* GTPase activation. In this regard, reduction of *DOCK4* expression in breast cancer patients has been reported⁽¹⁴⁾. Considering the function of *DOCK4* and *RAP1* genes and also their location at a locus of a chromosome in which high frequency LOH has been reported for the majority of breast cancers, it can be deduced that these two genes are tumor suppressor genes.

In this study promoter analysis of *DOCK4* gene in a benign tumor sample (fibroadenoma) revealed a heterozygote mutation

C>G at position -303 (6.66%). Gene analysis showed three variations in the third intron of *RAP1* gene as follows: heterozygote mutation G>A (2.04%) in an adenoid cystic carcinoma at position +45, heterozygote variation G>T (6.66%) in a benign tumor (intraductal papilloma) at position +45 and a homozygote variation T>A (6.66%) in a benign tumor (fibroadenoma) at position +29. Statistical tests showed that variations and mutations in both genes are independent from the type of the disease. However, considering the allelic frequency of T>A this variation was observed just in 15 cases of benign breast tumor which is equivalent to two variations among 30 alleles. On the other hand no variation of this type was found among 100 normal subjects in the study which is equivalent to 200 alleles. Therefore its occurrence possibly is related to the type of the disease. Since no heterozygote variation of this type was found in case and control groups it should be considered that probably SSCP method is not able to detect the heterozygote variant and other screening methods like RFLP, ASO or sequencing should be applied to determine the exact frequency of this variation.

In summary DNA samples from 64 cases of sporadic breast tumors were screened and the observed variations in *DOCK4* and *RAP1A* genes were compared with the control group (100 normal women). Although this study did not reveal any decisive pathological mutation but it uncovered four variants at low frequency that one of them was new and unclassified (G>A variant in a benign tumor sample at position +45 of the third intron of *RAP1A* gene). As a result, performing new studies to decipher the significance of these variants is indicated.

Acknowledgement

We would like to express our sincere gratitude to all principal investigators and research assistants of Genetic Research Centre, Social Welfare and Rehabilitation Sciences University, who have contributed to this study.

References

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. *CA Cancer J Clin* 2005;55(2):74-108.
2. Mousavi SM, Montazeri A, Mohagheghi MA, Jarrahi AM, Harirchi I, Najafi M, et al. Breast cancer in Iran: an epidemiological review. *Breast J* 2007;13(4):383-391.
3. Hedau S, Jain N, Husain SA, Mandal AK, Ray G, Shahid M, et al. Novel germ line mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India. *Breast Cancer Res Treat* 2004;88(2):177-186.
4. Osborne C, Wilson P, Tripathy D. Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. *Oncologist* 2004;9(4):361-377.
5. Mitchell EL, Santibanez-Koref MF. 1p13 is the most frequently involved band in structural chromosomal rearrangements in human breast cancer. *Genes Chromosomes Cancer* 1990;2(4):278-289.
6. Price LS, Hajdo-Milasinovic A, Zhao J, Zwartkruis FJ, Collard JG, Bos JL. RAP1 regulates E-cadherin-mediated cell-cell adhesion. *J Biol Chem* 2004;279(34):35127-35132.
7. Bieche I, Champeme MH, Matifas F, Cropp C, Callahan R, Lidereau R. Demonstration of two regions involved in chromosome 1p deletion in breast tumors. *Bull Cancer* 1994;81(2):108-113.
8. Bieche I, Khodja A, Lidereau R. Deletion mapping of chromosomal region 1p32-pter in primary breast cancer. *Genes Chromosomes Cancer* 1999;24(3):255-263.
9. Yajnik V, Paulding C, Sordella R, McClatchey AI, Saito M, Wahrer DC, et al. DOCK4, a GTPase activator, disrupted during tumorigenesis. *Cell* 2003;112(5):673-684.
10. Reif K, Cyster J. The CDM protein DOCK2 in lymphocyte migration. *Trends Cell Biol* 2002;12(8):368-373.
11. Nolan KM, Barrett K, Lu Y, Hu KQ, Vincent S, Settleman J. Myoblast city, the Drosophila homolog of DOCK180/CED-5, is required in a Rac signaling pathway utilized for multiple developmental processes. *Genes Dev* 1998;12(21):3337-3342.
12. Schmutzler RK, Homann A, Bierhoff E, Wiestler OD, Von Daimling A, Krebs D. Detection of genetic alterations in sporadic breast tumors. *Gynakol Geburtshilfliche Rundsch* 1995;35(Suppl 1):63-67.

13. Sztan M, Besznyak , Kovacs T, Toth J, Szemel , Olah E. Lack of correlation between survival and allele loss on chromosome 7q31-32 in primary breast cancer. *Pathol Oncol Res* 1996;2(1-2): 48-51.
14. Balkhi SS. Semiquantitative analysis of RAPIA gene expression in sporadic breast cancer. Dissertation submitted for MSc in Human Genetics, 2006, Genetic Research Centre, Social welfare and Rehabilitation Sciences University.
15. National Center for Biotechnology Information, U.S. National Library of Medicine [Internet], Bethesda (MD) [updated 2009 February 4; cited 2009 April 18]. Available from: <http://www.ncbi.nlm.nih.gov/>.
16. Genome browse ENSEMBL [internet] Cambridge [updated 2009 March 3; cited 2009 April 18]. Available from: <http://www.ensembl.org/index.html/>.
17. McPromoter MM:II- The Markov Chain promoter Prediction Server [internet] Nuremberg [updated 2005 August 15; cited 2009 April 18] Available from: <http://tools.genome.duke.edu/generegulation/McPromoterMMII/>.
18. Genomatix Software Gmbh [internet] [1998-2009; cited 2009 April 18]. Available from: <http://www.genomatix.de/cgi-in/dialign/dialign.pl/>.
19. Consite: web-based prediction of regulatory elements using cross-species comparison [internet] Stockholm [cited 2009 April 18]. Available from: <http://asp.ii.uib.no:8090/cgi-in/CONSITE/consite/>.
20. Tandem Repeats Finder [internet] Boston [updated 2003 September 11; cited 2009 April 18]. Available from: <http://tandem.bu.edu/trf/trf.submit.options.html/>.
21. Primer3 (v. 0.4.0) Pick primers from a DNA sequence [internet] NIH, Bethesda [updated 2007 February 7; cited 2009 April 18]. Available from: <http://frodo.wi.mit.edu/>.